Skye Bioscience has announced it will discontinue clinical development and spending in ophthalmology and instead refocus on its obesity drug candidate.
In a media release, the company said the Phase 2a clinical trial of SBI-100, an ophthalmic emulsion intended to lower intraocular pressure (IOP) in glaucoma patients, did not meet its primary endpoint.
Skye Bioscience said the ophthalmic emulsion did not achieve a statistically significant improvement in IOP over placebo. The drug was safe and all treated patients completed the study with no early discontinuations due to adverse events.
Skye intends to discontinue clinical development and spending related to SBI-100 and any research and development associated with its ophthalmology pipeline, and direct all clinical development resources to its metabolic program.
With this data outcome from our glaucoma program, we will now focus 100% of our efforts on broadening our metabolic clinical pipeline
“With this data outcome from our glaucoma program, we will now focus 100% of our efforts on broadening our metabolic clinical pipeline,” said Punit Dhillon, Skye’s CEO and Chair.
Skye’s Phase 2 obesity clinical trial for its differentiated CB1 inhibitor, Nimacimab, is expected to begin dosing later this year.
Reference
- Skye Bioscience, Skye Concentrates Strategy and Clinical Development Focus on Nimacimab Metabolic Program (media release, 10 June 2024), available at: ir.skyebioscience.com/news-events/press-releases/detail/197/skye-concentrates-strategy-and-clinical-development-focus [accessed 11 June 2024].
